Gyre Therapeutics (GYRE) News Today $7.74 -0.54 (-6.52%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.04 +0.30 (+3.81%) As of 08/29/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Research Analysts Issue Forecasts for GYRE Q3 EarningsAugust 30 at 6:31 AM | marketbeat.comAnalysts Offer Predictions for GYRE Q3 EarningsAugust 29 at 2:19 AM | americanbankingnews.comGyre Therapeutics (NASDAQ:GYRE) Now Covered by Analysts at HC WainwrightAugust 28 at 8:19 AM | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Now Covered by HC WainwrightAugust 28 at 2:19 AM | americanbankingnews.comGyre Therapeutics initiated with a Buy at H.C. WainwrightAugust 27 at 2:34 AM | msn.comHC Wainwright & Co. Initiates Coverage of Gyre Therapeutics (GYRE) with Buy RecommendationAugust 27 at 2:34 AM | msn.comGyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of DirectorsAugust 22, 2025 | globenewswire.comGyre Therapeutics' (NASDAQ:GYRE) Profits Appear To Have Quality IssuesAugust 18, 2025 | uk.finance.yahoo.comUS Undiscovered Gems 3 Promising Small Caps with Strong PotentialAugust 13, 2025 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Down Following Weak EarningsAugust 13, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Announces Quarterly Earnings ResultsAugust 12, 2025 | marketbeat.comGyre Therapeutics Inc.: Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership UpdateAugust 12, 2025 | finanznachrichten.deGyre Therapeutics CEO DepartsAugust 11, 2025 | marketwatch.comGyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership UpdateAugust 11, 2025 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 1.4% - Time to Buy?August 8, 2025 | marketbeat.comGyre Therapeutics (GYRE) Expected to Announce Earnings on TuesdayAugust 6, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 5.9% - Time to Sell?July 15, 2025 | marketbeat.comGyre Therapeutics: Unique Business Model, Unique ChallengesJune 30, 2025 | seekingalpha.comGYRE - Gyre Therapeutics Inc Sustainability - MorningstarJune 26, 2025 | morningstar.comMGyre Therapeutics, Inc. (GYRE) Latest Press Releases & Corporate News - Yahoo FinanceJune 24, 2025 | ca.finance.yahoo.comPublic companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%June 20, 2025 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 4% - Here's What HappenedJune 17, 2025 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest UpdateJune 15, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 6% - What's Next?June 11, 2025 | marketbeat.comGNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in ChinaJune 11, 2025 | msn.comGyre Therapeutics Inc.: Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | finanznachrichten.deGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Sees Large Volume Increase - Here's WhyJune 3, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 7.9% - What's Next?June 3, 2025 | marketbeat.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 31, 2025 | finance.yahoo.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 30, 2025 | msn.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 29, 2025 | finance.yahoo.comInsider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of StockMay 29, 2025 | marketbeat.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 29, 2025 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume - Should You Buy?May 29, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - What's Next?May 28, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - What's Next?May 25, 2025 | marketbeat.comGyre Therapeutics launches public stock offeringMay 24, 2025 | investing.comGyre Therapeutics announces new stock offeringMay 24, 2025 | uk.investing.comGyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB ...May 24, 2025 | morningstar.comMGyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025May 24, 2025 | nasdaq.comGyre Therapeutics Announces Commencement of Underwritten Public Offering of Common StockMay 24, 2025 | nasdaq.comGyre Therapeutics Shares Fall as Stock Offering Overshadows Positive Trial DataMay 23, 2025 | marketwatch.comGyre Therapeutics Announces Proposed Underwritten Public Offering of Common StockMay 23, 2025 | finance.yahoo.comGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common StockMay 23, 2025 | finance.yahoo.comGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common StockMay 22, 2025 | globenewswire.comGyre Therapeutics Announces Proposed Underwritten Public Offering of Common StockMay 22, 2025 | globenewswire.comGyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in ChinaMay 22, 2025 | globenewswire.comMajor Exercise Alert: Weiguo Ye Exercises Options Worth $478K At Gyre TherapeuticsMay 15, 2025 | benzinga.comGyre Therapeutics (NASDAQ:GYRE) Trading 14.3% Higher - Still a Buy?May 14, 2025 | marketbeat.com Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GYRE Media Mentions By Week GYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GYRE News Sentiment▼0.711.05▲Average Medical News Sentiment GYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GYRE Articles This Week▼132▲GYRE Articles Average Week Get the Latest News and Ratings for GYRE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Gyre Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Bausch Health Cos News Today Kymera Therapeutics News Today Scholar Rock News Today Amneal Pharmaceuticals News Today Xenon Pharmaceuticals News Today Crinetics Pharmaceuticals News Today HUTCHMED News Today Ultragenyx Pharmaceutical News Today MorphoSys News Today Arrowhead Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GYRE) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GYRE Stock Alerts